Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center.
Saved in:
| Title: | Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. |
|---|---|
| Authors: | Gibb A; The Christie NHS Foundation Trust, Manchester, UK., Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J |
| Source: | Haematologica [Haematologica] 2013 Apr; Vol. 98 (4), pp. 611-4. Date of Electronic Publication: 2012 Oct 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
